
Hermetica Superfood Encyclopedia
Legacy index-continuity record: the score and narrative are provisional and must not be represented as validated or human-approved.
Review flags: AWAITING_SEMANTIC_VALIDATION
Inositol hexanicotinate is a non-flushing form of niacin (vitamin B3) that releases nicotinic acid slowly through enzymatic hydrolysis. This sustained-release mechanism provides cardiovascular and metabolic benefits without the uncomfortable skin flushing associated with regular niacin.

Reported Benefits (Provisional)
Origin & History

Inositol Hexanicotinate is a form of niacin (vitamin B3) bound to inositol, designed to provide niacin benefits without the common flushing side effect. It is synthesized through a chemical reaction that combines six molecules of niacin with one molecule of inositol.
Research Narrative (Provisional)
Inositol Hexanicotinate has been studied for its effects on lipid levels, with some studies suggesting it may help lower cholesterol without the flushing effect of standard niacin.
Preparation & Dosage
Dosage guidance is withheld because the publication gate has not recorded adequate support for this profile.
Nutritional Profile
{"macronutrients": {"protein": "0g", "fat": "0g", "carbohydrates": "0g"}, "micronutrients": {"vitamins": {"Vitamin B3 (Niacin)": "500mg per serving (as Inositol Hexanicotinate)"}, "minerals": {}}, "bioactive_compounds": {"Inositol Hexanicotinate": "500mg per serving"}, "bioavailability_notes": "Inositol Hexanicotinate is a form of niacin that is slowly hydrolyzed to free niacin and inositol in the body, providing a sustained release and minimizing flushing effects commonly associated with niacin. The bioavailability of niacin from Inositol Hexanicotinate is lower compared to immediate-release niacin, but it is better tolerated."}
Reported Mechanism (Provisional)
Inositol hexanicotinate undergoes gradual hydrolysis by tissue esterases, slowly releasing nicotinic acid into circulation. The released niacin inhibits hormone-sensitive lipase in adipose tissue, reducing free fatty acid mobilization and subsequently decreasing hepatic VLDL synthesis. Unlike immediate-release niacin, this gradual release prevents prostaglandin D2-mediated vasodilation that causes skin flushing.
Clinical Narrative (Provisional)
Small-scale studies with 30-60 participants have shown inositol hexanicotinate can reduce LDL cholesterol by 10-20% and increase HDL by 15-25% over 8-12 weeks. However, most research comes from older, limited trials with methodological constraints. Some studies suggest comparable lipid benefits to regular niacin but with significantly reduced flushing episodes. More robust clinical data is needed to establish definitive therapeutic efficacy compared to standard niacin formulations.
Also Known As
Research updates — and 25% off your first order
Join our list for source-aware wellness education, review-state updates, and product news — and unlock 25% off your first Hermetica order. Educational content is not medical advice. No spam, unsubscribe anytime.







